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Background
Neutralizing antibody is a crucial parameter in the evalu-
ation of vaccine candidates and therefore, generating a rel-
evant neutralization assay has been a major focus of
research. Four critical variables are the viruses, the cells
they were grown in, the target cells, and the mode of
detection used in the assay. In order to standardize the
PBMC-based assay, we are generating primary isolate-
derived full-length infectious molecular clones (IMC)
from HIV+ individuals representing subtypes A, B, C, D,
CRF01_AE, and CRF02_AG. Each of these primary isolate
IMCs is then modified to express the Renilla luciferase
gene.
Methods
Renilla Luciferase gene isolated from pNL4.3_LucR.T2A
(C. Jambor) was inserted in full-length HIV-1 IMC. The
cloning was done without deleting any part of the HIV
genome. For each IMC_LucRT2A generated, the corre-
sponding env was cloned in pDNA3.1His to be used in
pseudovirus TZM-bl-assay. Viral stocks were generated by
transfection of 293T cells. Every construct was fully
sequenced; only sequences with 100% amino acid
sequence homology with the parental IMC were retained.
Results
We have so far generated 3 IMC_LucR; B-pWR27-
1_LucR.T2A (subtype B), C-pETH2220-11B_LucR.T2A
(subtype C) and 01-pCM235-2_LucR.T2A (CRF_01A/E).
The IMC_LucR.T2A were tested for infection in TZMbl
cells and PBMC. Compared with cognate IMC, the
IMC_LucR.T2A showed a similar profile of infection.
TZMbl NAb assays with different concentrations of mon-
oclonal antibodies (4E10, 2G12 and, b12), soluble CD4
(sCD4), Clade B and C serum pools showed an equivalent
50% neutralization titer when comparing IMC and corre-
sponding IMC_LucRT2A with non-significant, <3 fold dif-
ference between IMC and IMC_LucRT2A.
Conclusion
These encouraging data suggest that the IMC-LucRT2A pri-
mary isolate viruses may be used as a substitute for the tra-
ditional p24-based PBMC NAb assay.
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